SequelSEC

SI-BONE, Inc. SIBN

Surgical & Medical Instruments & Apparatus · CIK 0001459839 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$213.60M
Fiscal year ended 2026-06-30
Operating income
-$17.74M
Fiscal year ended 2026-06-30
Free cash flow
-$4.39M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$800.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$18.11Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity4.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio8.55x89th
Gross margin79.6%86th
Long-term debt / equity0.20x28th
Revenue YoY growth20.2%68th
SBC / revenue12.7%64th
Net margin-9.4%63th
R&D / revenue8.7%37th
CapEx / revenue4.2%57th
Operating margin-11.1%56th
FCF margin-4.5%53th

SI-BONE, Inc. (SIBN) reported revenue of $213.60M and net income of -$14.63M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from SI-BONE, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

SI-BONE, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$213.60M
Cost of revenue$43.73M
Gross profit$169.87M
Operating income-$17.74M
Net income-$14.63M
Research & development$18.02M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$169.60M
General & administrative$40.00M
Selling & marketing$129.59M

Balance

SI-BONE, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$33.13M
Total assets$248.76M
Current assets$219.91M
Total liabilities$66.41M
Current liabilities$24.04M
Total equity incl. NCI$182.35M
Temporary (mezzanine) equityUnavailable
Inventory$38.39M
Accounts receivable$31.18M
GoodwillUnavailable
Long-term debt$35.63M
Accounts payable$8.54M

Cash flow

SI-BONE, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$2.48M
Capital expenditures$6.86M
Investing cash flow-$5.97M
Financing cash flow$2.70M
Net change in cash-$1.02M
Stock-based compensation$24.21M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$6.42M

Derived

SI-BONE, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$4.39M
Gross margin79.5%
Operating margin-8.3%
FCF margin-2.1%
SBC / revenue11.3%
Current ratio9.15x
Revenue YoY growth15.3%
Net margin-6.9%
R&D / revenue8.4%
CapEx / revenue3.2%
Long-term debt / equity0.20x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SIBN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.